Top entities: Zenas BioPharma, Cohen Milstein Sellers & Toll, Molly J. Bowen, United States — United States District Court for the Northern District of California.

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business class action

Zenas BioPharma IPO Securities Fraud

Q: When did this event occur?

First reported Apr 17, 2025; last updated May 05, 2025.

Q: What is the market impact?

General. The market is negatively impacted by the alleged misleading statements from Zenas BioPharma, leading to a significant drop in its stock price.

Q: What were the key actions taken?

Zenas BioPharma misled investors · Cohen Milstein Sellers & Toll filed class action lawsuit Zenas BioPharma · Zenas BioPharma revised funding estimate

Analysis based on 8 articles · First reported Apr 17, 2025 · Last updated May 05, 2025

Sentiment

-70

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the alleged misleading statements from Zenas BioPharma, leading to a significant drop in its stock price. This event highlights the risks associated with IPOs and potential securities fraud, potentially increasing scrutiny on new public offerings.

Biotechnology Legal Services

Event Summary

Zenas BioPharma, a clinical-stage biopharmaceutical company, is facing a class action lawsuit filed by Cohen Milstein Sellers & Toll. The lawsuit alleges that Zenas BioPharma misled investors during its September 2024 IPO by falsely claiming it had sufficient cash to fund operations for 24 months. Less than two months later, Zenas BioPharma disclosed in its Q3 2024 filing that it could only sustain operations for 12 months. This revision caused Zenas BioPharma's shares to tumble nearly 49% from its IPO price of $17.00 to $8.72 by April 15, 2025. Investors who purchased shares in the IPO have until June 16, 2025, to seek appointment as lead plaintiff in the lawsuit filed in the United States — United States District Court for the Northern District of California.

Key Actions

100 Zenas BioPharma misled investors

95 Cohen Milstein Sellers & Toll filed class action lawsuit Zenas BioPharma

90 Zenas BioPharma revised funding estimate

Entities Involved

priv

Zenas BioPharma

Zenas BioPharma is the defendant in a class action lawsuit for allegedly misleading investors about its financial stability during its September 2024 IPO. Its stock price has fallen nearly 49% since the IPO.

Importance 100.0 Sentiment -90.0

priv

Cohen Milstein Sellers & Toll

Cohen Milstein Sellers & Toll is the law firm investigating and leading the class action lawsuit against Zenas BioPharma, encouraging investors to join.

Importance 80.0 Sentiment 70.0

per

Molly J. Bowen

Molly J. Bowen is a partner at Cohen Milstein Sellers & Toll and is the primary contact for investors interested in joining the class action lawsuit against Zenas BioPharma.

Importance 50.0 Sentiment 60.0

govactor

United States — United States District Court for the Northern District of California

Importance 0.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard